Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 3/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5805420 | 0.78 | RET (0.43) | RETCHEK1AXLPI4KAPI4K2B | |
| SCHEMBL154600 | 0.78 | CHEK1 (0.61) | MAPK1CHEK1BRAFTNNI3KAXL | |
| SCHEMBL7885565 | 0.78 | MAPK1 (0.39) | MAPK1CHEK1BRAFTNNI3KAXL | |
| SCHEMBL19306619 | 0.78 | BRAF (0.41) | MAPK1CHEK1BRAFTNNI3KAXL | |
| SCHEMBL6531144 | 0.77 | RET (0.42) | RETCHEK1BRAFTNNI3KPI4KA | |
| SCHEMBL6469764 | 0.76 | BRAF (0.43) | MAPK1CHEK1BRAFTNNI3KAXL | |
| SCHEMBL23735452 | 0.75 | CHEK1 (0.48) | RETCHEK1BRAFTNNI3KPI4KA | |
| SCHEMBL10259826 | 0.75 | AKT1 (0.45) | RETCHEK1BRAFTNNI3KAKT1 | |
| SCHEMBL397485 | 0.75 | CHEK1 (0.63) | RETMAPK1CHEK1AXLPI4KA | |
| SCHEMBL8107167 | 0.73 | FLT3 (0.46) | RETMAPK1CHEK1AXLLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522605-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119638639-A | Biaryl compound with anti-cell necrotic apoptosis activity, derivative and application thereof | 中国药科大学 | 2025-03-18 | — | — | CN | disclosed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| CN-114126620-B | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101917999-A | Modulation of protein trafficking | FOLDRX PHARMACEUTICALS INC | 2010-12-15 | — | — | CN | disclosed |
| US-5324731-A | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated | AMIRA, INC. (US) | 1994-06-28 | — | — | US | disclosed |
| EP-0557383-A1 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
| WO-1992008456-A2 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | RET 2772/4885MAPK1 5/4885CHEK1 897/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | RET 3063/4885MAPK1 1386/4885CHEK1 4135/4885 |
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | SRC, LCK, FYN | RET 56/4885MAPK1 412/4885CHEK1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.